What were the key takeaways from Alector's earnings call?

What is the revenue and EPS growth rate for Alector year over year?

Did Alector beat or miss consensus estimates last quarter?

What factors drove the changes in Alector's revenue and profit?

What is the market's earnings forecast for Alector next quarter?

What were the key takeaways from Alector’s earnings call?

What is Alector's gross profit margin?

What is Alector's latest dividend and current dividend yield?

- **Pivotal FTD-GRN Data Imminent**: Phase III INFRONT-3 readout expected mid-Q4 2025, with co-primary endpoints of clinical progression slowing (CDR-NACC-FTLD) and progranulin normalization.
- **Alzheimer's Pipeline Progression**: AL101 Phase II trial completed enrollment, targeting GRN mutation-linked AD pathophysiology.
- **Strong Financial Position**: $307.3M cash runway into 2027, supporting dual late-stage programs and pipeline expansion.
- **FDA Alignment**: Agency认可progranulin as confirmatory endpoint, reinforcing mechanistic rationale.
- **Near-Term Catalysts**: Latozinemab BLA submission anticipated Q2 2026 if data meet pre-specified criteria.

**【CEO Summary Section】**
- Alector is nearing a pivotal inflection point with the mid-Q4 readout of Phase III INFRONT-3 trial for latozinemab in FTD-GRN. 
- Latozinemab is the first progranulin-elevating therapy targeting the root cause of FTD-GRN, with Phase II data showing 2-3x progranulin normalization and 48% slowing of disease progression.
- AL101, a next-gen progranulin antibody, is advancing in Phase II for early Alzheimer's disease, leveraging genetic evidence linking GRN mutations to AD risk.

**【Clinical Overview (Dr. Darby)】**
- FTD-GRN affects ~5-10% of FTD cases (~8,000-17,000 U.S./EU patients), caused by GRN mutations leading to progranulin deficiency.
- Current management is symptomatic; no approved disease-modifying therapies exist.
- Biomarkers like neurofilament light (NfL) and MRI volumetrics enable earlier diagnosis and tracking of neurodegeneration.

**【CMO Financial Commentary】**
- INFRONT-3 Phase III trial: 103 symptomatic/16 presymptomatic GRN mutation carriers, powered to detect 40% slowing of disease progression (CDR-NACC-FTLD sum of boxes).
- FDA-amended statistical plan adds plasma progranulin as co-primary endpoint, reflecting mechanistic importance.
- Trial completion expected Q4 2025; BLA/MAA submissions anticipated Q2 2026.

**【R&D Pipeline Update】**
- Anti-amyloid beta antibody (ADP 037 ABC) engineered for brain penetration, reduced ARIA risk, and subcutaneous delivery.
- GCase replacement therapy (ADP 050 ABC) targets lysosomal dysfunction in Parkinson's and Gaucher disease.
- Additional programs include anti-tau siRNA, reelin modulators, and brain-penetrant enzyme therapies.

**【CFO Financial Update】**
- Q2 2025 cash balance: $307.3M, providing runway into H2 2027.
- 2025 guidance: Collaboration revenue ($13-18M), R&D ($130-140M), G&A ($55-65M).
- Focus on execution across clinical, preclinical, and research pipelines.

**【Q&A Highlights】**
- FDA requested progranulin as co-primary endpoint, reflecting mechanistic validation.
- Trial powered to detect 25% slowing of progression (statistically significant at p<0.05).
- No ARIA events observed; latozinemab safety profile remains clean.
- Open-label extension (Part 2) enrollment strong, providing long-term efficacy data.


Alector (ALEC)-7 Aug 25-2025 Q2 Earnings call transcript

- **FTD Clinical Milestone:** Phase 3 INFRONT-3 trial readout expected Q4 2024 with 90% power to detect 40% disease progression slowing.
- **Alzheimer's Pipeline Expansion:** AL101 Phase 2 trial enrollment on track for mid-2025 completion; ADP037-ABC IND submission planned for 2025.
- **ABC Platform Innovation:** ADP037-ABC targets validated Aβ epitope with optimized brain penetration; ADP050-ABC engineered GCase for Parkinson's therapy.
- **Financial Strength:** $413.4M cash balance as of Q4 2024; 2025 R&D budget ($175-185M) supports broad pipeline advancement.
- **Strategic Focus:** No immediate M&A plans; prioritizing internal programs with ABC platform versatility.


**【CEO Strategic Overview】**
- Alector focuses on developing first-in-class therapies for neurodegenerative diseases like FTD, Alzheimer's, and Parkinson's, targeting underlying mechanisms such as toxic proteins and immune dysfunction.
- The ABC (Alector Brain Carrier) platform enables efficient delivery of therapeutics across the blood-brain barrier, with wholly owned programs expected to enter the clinic in 2026.
- Key milestones include the Phase 3 INFRONT-3 trial readout for latozinemab in FTD (Q4 2024) and completion of patient recruitment for the Phase 2 PROGRESS-AD trial for AL101 in early Alzheimer's.

**【Clinical Development Updates】**
- **Latozinemab (INFRONT-3):** Pivotal Phase 3 trial with 103 symptomatic and 16 at-risk FTD granulin patients. Primary endpoint: 48-week change in CDR+FTLD score. 90% power to detect 40% slowing of progression; 25% slowing expected to be statistically significant. FDA granted Breakthrough Therapy Designation in 2024.
- **AL101 (PROGRESS-AD):** Phase 2 trial in early Alzheimer's with 282 patients. Evaluates safety and efficacy of two doses over 76 weeks. Primary endpoint: 76-week change in CDR sum of boxes. Enrollment expected to complete mid-2025.
- **AL002 (INVOKE-2):** Phase 2 trial results for TREM2 agonist in early Alzheimer's to be presented at AD/PD 2025 conference in April.

**【Preclinical Pipeline】**
- **ABC-Enabled Programs:**
  - ADP037-ABC: Anti-amyloid beta antibody targeting PyrGlu3 Aβ epitope, optimized for brain penetration and phagocytosis.
  - ADP050-ABC: GCase replacement therapy for Parkinson's, engineered for stability and activity.
  - Tau-targeting programs (antibody and siRNA) and Reelin modulator for Alzheimer's.
- IND-enabling studies for ADP037-ABC and ADP050-ABC expected in 2025, with clinic entry in 2026.

**【Financial Highlights】**
- Cash position: $413.4M as of Q4 2024.
- 2024 Collaboration Revenue: $100.6M (vs. $97.1M in 2023).
- 2024 R&D Expenses: $185.9M (vs. $192.1M in 2023).
- 2025 Financial Outlook:
  - Collaboration Revenue: $5-15M
  - R&D Expenses: $175-185M
  - G&A Expenses: $55-65M

**【Q&A Key Takeaways】**
- **INFRONT-3 Enrollment Strategy:** Focused on early symptomatic patients (CDR+FTLD score 0.5-2) to maximize efficacy potential. Presymptomatic patients included in sensitivity analysis.
- **ABC Platform Differentiation:** Versatile tunable design enables optimized efficacy/safety tradeoffs. ADP037-ABC targets validated Aβ epitope with Fc functionality for plaque clearance.
- **Funding Strategy:** No immediate plans for M&A or out-licensing; prioritizing internal pipeline advancement with strong cash position.
- **TREM2 vs. Progranulin:** Mechanisms are distinct; no direct read-through between trials. Biomarkers (progranulin, NfL) aligned with FDA for supportive evidence in INFRONT-3.


Actual						-0.53	-0.58	-0.67	-0.66	-0.66	-0.69	1.49	-0.68	-0.54	0.12	-0.56	-0.63	-0.55	0.02	-0.53	-0.49	-0.38	-0.4	-0.43	-0.02	-0.41	-0.3
Forecast						-0.4395	-0.4994	-0.5356	-0.6466	-0.6917	-0.6656	2.4985	-0.1732	0.4671	-0.4693	-0.4656	-0.4636	-0.7586	-0.8135	-0.6574	-0.771	-0.5081	-0.501	-0.534	-0.6225	-0.4841	-0.4614
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	-20.59%	-16.14%	-25.09%	-2.07%	+4.58%	-3.67%	-40.36%	-292.61%	-215.61%	+125.57%	-20.27%	-35.89%	+27.50%	+102.46%	+19.38%	+36.45%	+25.21%	+20.16%	+19.48%	+96.79%	+15.31%	+34.98%

ALEC

ALEC fundamentals

ALEC Q2 2025 Earnings

Earnings Call

You can ask Aime

ALEC

ALEC fundamentals

ALEC Q2 2025 Earnings

Earnings Call

ALEC Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

ALEC Earnings Call Summary for Q1/2025 Mar 25, 2026

ALEC Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

ALEC Earnings Call Summary for Q3/2024 Mar 25, 2026

ALEC Earnings Call Summary for Q2/20244:30 PM on Aug 7, 2024

You can ask Aime